title: Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program.
abstract: METHODS
  Allogeneic bone marrow transplantation is curative in a substantial number of patients with hematologic cancers, marrow-failure disorders, immunodeficiency syndromes, and certain metabolic diseases. Unfortunately, only 25 to 30 percent of potential recipients have HLA-identical siblings who can act as donors. In 1986 the National Marrow Donor Program was created in the United States to facilitate the finding and procurement of suitable marrow from unrelated donors for patients lacking related donors.
  
  
  RESULTS
  During the first four years of the program, 462 patients with acquired and congenital lymphohematopoietic disorders or metabolic diseases received marrow transplants from unrelated donors. The probability of engraftment by 100 days after transplantation was 94 percent, although 8 percent of patients later had secondary graft failure. The probability of grade II, III, or IV acute graft-versus-host disease was 64 percent, and the probability of chronic graft-versus-host disease at one year was 55 percent. The rate of disease-free survival at two years among patients with leukemia and good prognostic factors was 40 percent and among patients at higher risk, 19 percent. Twenty-nine percent of the patients with aplastic anemia were alive at two years, and the rate of two-year disease-free survival among patients with myelodysplasia was 18 percent. For patients with congenital immunologic or nonimmunologic disorders, the probability of survival was 52 percent.
  
  
  CONCLUSIONS
  The National Marrow Donor Program has benefited a substantial number of patients in need of marrow transplants from closely HLA-matched unrelated donors and has facilitated the recruitment of unrelated donors into the donor pool and the access to suitable marrow.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: N A
authors.initials: NA
authors.lastname: Kernan
authors.forename: G
authors.initials: G
authors.lastname: Bartsch
authors.forename: R C
authors.initials: RC
authors.lastname: Ash
authors.forename: P G
authors.initials: PG
authors.lastname: Beatty
authors.forename: R
authors.initials: R
authors.lastname: Champlin
authors.forename: A
authors.initials: A
authors.lastname: Filipovich
authors.forename: J
authors.initials: J
authors.lastname: Gajewski
authors.forename: J A
authors.initials: JA
authors.lastname: Hansen
authors.forename: J
authors.initials: J
authors.lastname: Henslee-Downey
authors.forename: J
authors.initials: J
authors.lastname: McCullough
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000601:surgery; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000706:statistics & numerical data*; D002423:Cause of Death; D002648:Child; D003625:Data Collection; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007938:Leukemia / Q000601:surgery; D008297:Male; D008875:Middle Aged; D015996:Survival Rate; D014019:Tissue Donors / Q000706:statistics & numerical data*; D009927:Tissue and Organ Procurement; D014184:Transplantation, Homologous; D014481:United States
chemical_list: D006680:HLA Antigens